---
deleted: true
tags: [Import-6182]
title: Antipsychotic_combinations.md
created: '2021-06-17T10:39:38.457Z'
modified: '2021-06-18T15:46:32.615Z'
---

# Antipsychotic_combinations.md

 \*\*Should we combine antipsychotics\** Maudsley 13th edition Read by Dr Hardik Present Dr. Dinesh, Dr. Jagdish, Dr Ankur ![](../../attachments/reb-tail.jpg) # Ground realites - 1 in 6 receives combination antipsychotics - UK study - May be more in India [Data needs to be reviewed] # Indications - Cross tapering - Resitant schizophrenia (reduce residual psychosis symptoms) - To reduce eide effects of one antipsychotic (e.g. If clozapine induced wt gain or hyperprolactinemia then add arip to reduce wt gain or hyperprolcatinemia) # Why we shouldn't combine? - Little evidence base for combining non-clozpaine antipsychotic medications - Substantial evidence for harm - Increased side effects - Reduced cognitive functions - Combination over 10 year - increased risk of death - 3 antipsychotic combination - 3 times risk of mortality - Evidence suggests that even in case of Clozapine - combinations improve tolerability but not efficacy # Good practices - Antipsychotic polypharmacy should be avoided - Document rationalie for combining antipsychotics - Monitor for side effects with greater acuity - Final target should be to stabilize the patient on one antipsychotic - Changing to single drug lead to better cognitive function [JRV view outcome in schizophrenia may be a more significantly predicted by cogntive functions] ![](../../attachments/reb-tail.jpg) body{visibility:hidden;white-space:pre;font-family:monospace}window.alreadyProcessedMarkdeep||(document.body.style.visibility="visible")
